Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 6Phase 1/2 4Phase 3 2Phase 2/3 1

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Lung Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × tanespimycin × Clear all
NCT00773344 2015-11-04

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

Bristol-Myers Squibb

Phase 1/2 Completed
25 enrolled
Breast

Breast Neoplasms

NCT01427946 2014-11-13

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

Infinity Pharmaceuticals, Inc.

Phase 1/2 Completed
47 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00431015 2012-12-10

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Infinity Pharmaceuticals, Inc.

Phase 1/2 Completed
88 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00627627 2010-02-03

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

MedImmune LLC

Phase 1/2 Withdrawn
56 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡